SCHEMBL1035455

SCHEMBL1035455

COc1cc(Nc2ncc(F)c(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)n2)cc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.58
BTK Q06187 4/20 0.57
FAM20C Q8IXL6 1/20 0.57
ITK Q08881 5/20 0.57
EGFR P00533 4/20 0.57
ADORA3 P0DMS8 2/20 0.54
TYRO3 Q06418 2/20 0.54
AURKA O14965 7/20 0.52
GSK3A P49840 4/20 0.51
PLK4 O00444 3/20 0.51
PDPK1 O15530 3/20 0.51
JAK2 O60674 3/20 0.51
PRKD3 O94806 3/20 0.51
NTRK1 P04629 3/20 0.51
INSR P06213 3/20 0.51
LCK P06239 3/20 0.51
FYN P06241 3/20 0.51
CSF1R P07333 3/20 0.51
IGF1R P08069 3/20 0.51
ROS1 P08922 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12726303 0.93 EGFR (0.65) SYKBTKITKEGFRADORA3
Hydrochloric Acid SCHEMBL1037848 0.92 EGFR (0.64) SYKBTKITKEGFRADORA3
SCHEMBL1037441 0.92 SYK (0.56) SYKBTKFAM20CITKEGFR
SCHEMBL1221693 0.91 SYK (0.64) SYKBTKITKEGFRADORA3
SCHEMBL1038608 0.90 PTK2 (0.57) SYKBTKITKEGFRADORA3
SCHEMBL1038905 0.88 SYK (0.54) SYKBTKFAM20CITKEGFR
SCHEMBL12894667 0.86 SYK (0.62) SYKBTKFAM20CITKEGFR
SCHEMBL1038876 0.86 SYK (0.56) SYKBTKITKEGFRADORA3
SCHEMBL1222113 0.85 EGFR (0.68) SYKBTKITKEGFRADORA3
SCHEMBL1033746 0.85 SYK (0.55) SYKBTKFAM20CITKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US claimed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP claimed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO claimed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS ZAP70, SYK, LCK SYK 2/4885BTK 4/4885FAM20C 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.